Regarding BCL2, an immunohistochemical analysis conducted within the Fondazione Italiana Linfomi (FIL) indicated that BCL2, an antiapoptotic protein, is overexpressed in 88% of patients with AITL, 80% of patients with PTCL-NOS, 58% of patients with ALK- ALCL, and 31% of patients with ALK+ ALCL (12). Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.